A controlled randomized open-label multicentre study evaluating if early initiation of everolimus (Certican) and early elimination of cyclosporine (Sandimmun Neoral) in de novo heart transplant recipients can improve long-term renal function and slow down the progression of chronic allograft vasculopathy.

Trial Profile

A controlled randomized open-label multicentre study evaluating if early initiation of everolimus (Certican) and early elimination of cyclosporine (Sandimmun Neoral) in de novo heart transplant recipients can improve long-term renal function and slow down the progression of chronic allograft vasculopathy.

Completed
Phase of Trial: Phase IV

Latest Information Update: 01 May 2016

At a glance

  • Drugs Everolimus (Primary) ; Ciclosporin; Corticosteroids; Mycophenolate mofetil
  • Indications Heart transplant rejection
  • Focus Therapeutic Use
  • Acronyms SCHEDULE
  • Sponsors Novartis
  • Most Recent Events

    • 30 Apr 2016 Virtual histology tissue morphology analysis (n=76) were presented at the 36th Annual Meeting and Scientific Sessions of the International Society for Heart and Lung Transplantation.
    • 17 Mar 2016 Results of a sub-study (n=74) published in the Journal of Heart and Lung Transplantation.
    • 28 Jan 2016 Results published in the American Journal of Transplantation
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top